Loading
NT5C2 (Cytosolic purine 5'-nucleotidase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 1 more.
Broad specificity cytosolic 5'-nucleotidase that catalyses the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates. In addition, possesses a phosphotransferase activity by which it can transfer a phosphate from a donor nucleoside monophosphate to an acceptor nucleoside, preferably inosine, deoxyinosine and guanosine. Has the highest activities for IMP and GMP followed by dIMP, dGMP and XMP.
CIViC holds 18 clinical evidence items and 0 assertions across 6 variants, naming Mercaptopurine, Thioguanine, Nelarabine and Arabinosylguanine and others. Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.75, genetic association 0.00, somatic mutation 0.97).
In plain words · NT5C2 (Cytosolic purine 5'-nucleotidase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 1 more.
NT5C2 (Cytosolic purine 5'-nucleotidase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 1 more.
Broad specificity cytosolic 5'-nucleotidase that catalyses the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates.
No product in this corpus aims at NT5C2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA NT5C2: RNA low tissue specificity; no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Lymphoma, Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas NT5C2 tissue; Open Targets ENSG00000076685 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Oka et al, Biochem. Biophys. Res. Commun, 1994, "Molecular cloning of human cytosolic purine 5'-nucleotidase". Source.
Sources: HGNC HGNC:8022 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49902 (protein name, function text, keywords and locations (REST API)); CIViC gene NT5C2 (18 evidence items, 0 assertions, 6 variants; diseases: Childhood Acute Lymphocytic Leukaemia, T-cell Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemia, B-lymphoblastic Leukaemia/lymphoma (GraphQL API, CC0)); Open Targets ENSG00000076685 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.53, non-Hodgkin lymphoma 0.55, breast cancer 0.50, leukaemia 0.55 (GraphQL API, CC0))
Broad specificity cytosolic 5'-nucleotidase that catalyses the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates. In addition, possesses a phosphotransferase activity by which it can transfer a phosphate from a donor nucleoside monophosphate to an acceptor nucleoside, preferably inosine, deoxyinosine and guanosine. Has the highest activities for IMP and GMP followed by dIMP, dGMP and XMP. Could also catalyse the transfer of phosphates from pyrimidine monophosphates but with lower efficiency. Through these activities regulates the purine nucleoside/nucleotide pools within the cell. Location: Cytoplasm, cytosol (UniProt). Locus 10q24.32-q24.33 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high; medium in Adipose tissue, Adrenal gland, Bone marrow, Bronchus, Colon, Endometrium and more.
No cancer stained high; medium in breast cancer, colorectal cancer, glioma, prostate cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"NT5C2" OR ABSTRACT:"NT5C2" OR TITLE:"5'-nucleotidase, cytosolic II" OR ABSTRACT:"5'-nucleotidase, cytosolic II" OR TITLE:"Cytosolic purine 5'-nucleotidase" OR ABSTRACT:"Cytosolic purine 5'-nucleotidase" OR TITLE:"PNT5" OR ABSTRACT:"PNT5" OR TITLE:"cN-II" OR ABSTRACT:"cN-II" OR TITLE:"SPG65" OR ABSTRACT:"SPG65") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NT5C2, not a curated reading list.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, Breast cancer (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Breast cancer (all types), Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.